Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia

Schizophrenia Research

Volumn 133, Issue 1-3, 2011, Pages 150-155

  Okusaga, Olaoluwa ^a,b   Langenberg, Patricia ^a   Sleemi, Aamar ^a,b   Vaswani, Dipika ^a   Giegling, Ina ^c   Hartmann, Annette M ^c   Konte, Bettina ^c   Friedl, Marion ^c   Groer, Maureen W ^d   Yolken, Robert H ^e   Rujescu, Dan ^c   Postolache, Teodor T ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b St Elizabeths Hospital   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Schizophrenia; Suicidal behavior; Toxoplasma gondii

Indexed keywords

GLIADIN ANTIBODY; IMMUNOGLOBULIN G;

ADULT; AGE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; FEMALE; GERMANY; HERPES SIMPLEX VIRUS 1; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ADULT; ANTIBODIES, PROTOZOAN; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE, ATTEMPTED; TOXOPLASMA; TOXOPLASMOSIS;

EID: 81955167989     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.08.006     Document Type: Article

References (52)

1. Arling T.A., Yolken R.H., Lapidus M., Langenberg P., Dickerson F.B., Zimmerman S.A., Balis T., Cabassa J.A., Scrandis D.A., Tonelli L.H., Postolache T.T. Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. J. Nerv. Ment. Dis. 2009, 197(12):905-908.
2. Barry S., Clarke G., Scully P., Dinan T.G. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J. Psychopharmacol. 2009, 23(3):287-294.
3. Berdoy M., Webster J.P., Macdonald D.W. Fatal attraction in rats infected with Toxoplasma gondii. Proc. Biol. Sci. 2000, 267(1452):1591-1594.
4. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br. J. Psychiatry 1997, 171(6):502-508.
5. Centers for Disease Control and Prevention, 2010. National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS): www.cdc.gov/ncipc/wisqars.
6. Colzato L.S., van den Wildenberg W.P., Van der Does A.J., Hommel B. Genetic markers of striatal dopamine predict individual differences in dysfunctional, but not functional impulsivity. Neuroscience 2010, 170(3):782-788.
7. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Ruslanova I., Yolken R.H. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry 2003, 60(5):466-472.
8. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Leister F., Yang S., Krivogorsky B., Alaedini A., Yolken R. Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biol. Psychiatry 2010, 68(1):100-104.
9. Dubey J.P., Jones J.L. Toxoplasma gondii infection in humans and animals in the United States. Int. J. Parasitol. 2008, 38(11):1257-1278.
10. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version 2002, (SCID-I/P), Biometrics Research, New York State Psychiatric Institute, New York. Patient Edition.
11. Gaskell E.A., Smith J.E., Pinney J.W., Westhead D.R., McConkey G.A. A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PLoS One 2009, 4:e4801.
12. Grant I.H., Gold J.W., Rosenblum M., Niedzwiecki D., Armstrong D. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS 1990, 4(6):519-521.
13. Hawton K., van Heeringen K. Suicide. Lancet 2009, 373(9672):1372-1381.
14. Inskip H.M., Harris E.C., Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br. J. Psychiatry 1998, 172:35-37.
15. Jones J.L., Kruszon-Moran D., Sanders-Lewis K., Wilson M. Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade. Am. J. Trop. Med. Hyg. 2007, 77(3):405-410.
16. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
17. Koseoglu E., Yazar S., Koc I. Is Toxoplasma gondii a causal agent in migraine?. Am. J. Med. Sci. 2009, 338(2):120-122.
18. Lidberg L., Belfrage H., Bertilsson L., Evenden M.M., Asberg M. Suicide attempts and impulse control disorder are related to low cerebrospinal fluid 5-HIAA in mentally disordered violent offenders. Acta Psychiatr. Scand. 2000, 101(15):395-402.
19. Linderholm K.R., Skogh E., Olsson S.K., Dahl M.L., Holtze M., Engberg G., Samuelsson M., Erhardt S. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 2010, doi:10.1093/schbul/sbq086 (Electronic publication ahead of print August 20, 2010).
20. Ling V.J., Lester D., Mortensen P.B., Langenberg P.W., Postolache T.T. Toxoplasma gondii seropositivity and suicide rates in women. J. Nerv. Ment. Dis. 2011, 199(7):440-444.
21. Mann J. Neurobiology of suicidal behaviour. Nat. Rev. Neurosci. 2003, 4(10):819-828.
22. Mann J.J., Arango V.A., Avenevoli S., Brent D.A., Champagne F.A., Clayton P., Currier D., Dougherty D.M., Haghighi F., Hodge S.E., Kleinman J., Lehner T., McMahon F., Moscicki E.K., Oquendo M.A., Pandey G.N., Pearson J., Stanley B., Terwilliger J., Wenzel A. Candidate endophenotypes for genetic studies of suicidal behavior. Biol. Psychiatry 2009, 65(7):556-563.
23. Meers S., Lagrou K., Theunissen K., Dierickx D., Delforge M., Devos T., Janssens A., Meersseman W., Verhoef G., Van Eldere J., Maertens J. Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation. Clin. Infect. Dis. 2010, 50(8):1127-1134.
24. Miller C.M., Boulter N.R., Ikin R.J., Smith N.C. The immunobiology of the innate response to T. gondii. Int. J. Parasitol. 2009, 39(1):23-39.
25. Miller C.M., Boulter N.R., Ikin R.J., Smith N.C. The immunobiology of the innate response to T.gondii. Int. J. Parasitol. 2009, 39(1):23-39.
26. Montoya J.G., Liesenfeld O. Toxoplasmosis. Lancet 2004, 363(9425):1965-1976.
27. Müller N., Myint A.-M., Schwarz M.J. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues Clin. Neurosci. 2009, 11(3):319-332.
28. Osborn D., Levy G., Nazareth I., King M. Suicide and severe mental illnesses. Cohort study within the UK general practice research database. Schizophr. Res. 2008, 99(1-3):134-138.
29. Palmer B.A., Pankratz V.S., Bostwick J.M. The lifetime risk of suicide in schizophrenia: a reexamination. Arch. Gen. Psychiatry 2005, 62(3):247-253.
30. Pompili M., Serafini G., Innamorati M., Lester D., Shrivastava A., Girardi P., Nordentoft M. Suicide risk in first episode psychosis: a selective review of the current literature. Schizophr. Res. 2011, 129(1):1-11.
31. Prandota J. Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in nonhuman immunodeficiency virus-infected subjects with no lymphadenopathy: the parasite may be responsible for the neurogenic inflammation postulated as a cause of different types of headaches. Am. J. Ther. 2007, 14(1):63-105.
32. Ressler K.J. Amygdala activity, fear, and anxiety: modulation by stress. Biol. Psychiatry 2010, 15(67):1117-1119.
33. Prandota J. Migraine associated with patent foramen ovale may be caused by reactivation of cerebral toxoplasmosis triggered by arterial blood oxygen desaturation. Int. J. Neurosci. 2010, 120(2):81-87.
34. Schwarcz R., Hunter C.A. Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid?. Schizophr. Bull. 2007, 33(3):652-653.
35. Seo D., Patrick C.J., Kennealy P.J. Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress. Violent Behav. 2008, 13(5):383-395.
36. Sequeira A., Mamdani F., Ernst C., Vawter M.P., Bunney W.E., Lebel V., Rehal S., Klempan T., Gratton A., Benkelfat C., Rouleau G.A., Mechawar N., Turecki G. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 2009, 4(8):e6585.
37. Shrivastava A., Johnston M.E., Shah N., Innamorati M., Stitt L., Thakar M., Lester D., Pompili M. Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension. Neuropsychiatr. Dis. Treat. 2010, 5(6):633-638.
38. Sublette E.M., Galfalvy H.C., Fuchs D., Lapidus M., Grunebaum M., Oquendo M.A., John Mann J., Postolache T.T. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav. Immun. 2011, 25(6):1272-1278.
39. Suda A., Kawanishi C., Kishida I., Sato R., Yamada T., Nakagawa M., Hasegawa H., Kato D., Furuno T., Hirayasu Y. Dopamine D2 receptor gene polymorphisms are associated with suicide attempt in the Japanese population. Neuropsychobiology 2009, 59(2):130-134.
40. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2007, 33(3):729-736.
41. Träskman L., Åsberg M., Bertilsson L., Sjöstrand L. Monoamine metabolites in CSF and suicidal behavior. Arch. Gen. Psychiatry 1981, 38(6):631-634.
42. Vyas A., Kim S.K., Giacomini N., Boothroyd J.C., Sapolsky R.M. Behavioral changes induced by T. gondii infection of rodents are highly specific to aversion of cat odors. Proc. Natl Acad. Sci. 2007, 10(104):6442-6447.
43. Wang H., Yolken R.H., Hoekstra P.J., Burger H., Klein H.C. Antibodies to infectious agents and the positive symptom dimension of subclinical psychosis: the TRAILS study. Schizophr. Res. 2011, 129(1):47-51.
44. Webster J.P. The effect of Toxoplasma gondii on animal behavior: playing cat and mouse. Schizophr. Bull. 2007, 33(3):752-756.
45. Wonodi I., Stine O.C., Sathyasaikumar K.V., Roberts R.C., Mitchell B.D., Hong L.E., Kajii Y., Thaker G.K., Schwarcz R. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch. Gen. Psychiatry 2011, 68(7):665-674.
46. Wu H.Q., Rassoulpour A., Schwarcz R. Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?. J. Neural Transm. 2007, 14(1):33-41.
47. Wu H.Q., Pereira E.F., Bruno J.P., Pellicciari R., Albuquerque E.X., Schwarcz R. The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J. Mol. Neurosci. 2010, 40(1-2):204-210.
48. Yagmur F., Yazar S., Temel H.O., Cavusoglu M. May Toxoplasma gondii increase suicide attempt-preliminary results in Turkish subjects?. Forensic Sci. Int. 2010, 199(1-3):15-17.
49. Yolken R.H., Bachmann S., Ruslanova I., Lillehoj E., Ford G., Torrey E.F., Schroeder J. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin. Infect. Dis. 2001, 32(5):842-844.
50. Yolken R.H., Dickerson F.B., Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol. 2009, 31(11):706-715.
51. Yolken R.H., Torrey E.F., Lieberman J.A., Yang S., Dickerson F.B. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr. Res. 2011, 128(1-3):61-65.
52. Zmarowski A., Wu H.Q., Brooks J.M., Potter M.C., Pellicciari R., Schwarcz R., Bruno J.P. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur. J. Neurosci. 2009, 29(3):529-538.